- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Deadline Today for $1B CMS Innovation Challenge
Letters of intent to take part in the CMS Innovation Center's Health Care Innovation Challenge, which promises up to $1 billion for new ideas that improve care, shift incentives and help train a newly-focused healthcare workforce, are due today.
CMS announced the contest, which is aimed at lowering costs for people enrolled in Medicare, Medicaid and CHIP, especially those with the highest health care needs, in November.
.
See also: HHS launches $1B innovation initiative
Anyone wishing to take part in the Health Care Innovation Challenge must first submit a non-binding letter of intent — meant to help CMS determine the expertise and personnel necessary to appropriately review applications and issue awards. Letters are due by 11:59 p.m. Eastern Time on Monday, December 19. Failure to submit one will disqualify the application from that organization from being reviewed during the first round of funding.
On a webinar this past Friday, CMS officials highlighted how the initiative is helping "rubber hit the road" when it comes to health reform, seeking out new and creative ways to design care models and train the health workforce.
The grant funding — with potential awards ranging from $1 million to $30 million is meant to spur creativity as individuals and group "do the hard work" of changing healthcare.
Read the full announcement a:http://healthcareitnews.com/news/deadline-today-1b-cms-innovation-challenge
Source: Healthcare IT News
Understanding How Fitness Affects Digestive Diseases
April 18th 2025Exercise is a powerful modulator of gut health in patients with gastrointestinal (GI) conditions, as moderate activity can ease gut inflammation, reduce colorectal cancer risk, and relieve constipation, while intense workouts may backfire, causing reflux, GI bleeding, or gut barrier disruption.
Read More
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Key Indicators of Myasthenia Gravis Disease Progression Reduced With Efgartigimod
April 18th 2025Research presented at the recent annual meeting of the Academy of Managed Care Pharmacy highlights outcomes among patients who have anti-acetylcholine receptor antibody-positive myasthenia gravis that include reduced exacerbations and need for immunoglobulin.
Read More
